Joseph Raevis
Ophthalmology · Little Silver, NJNPI 1508253048
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Alcon at 44.0% of the total. Reporting peaked in 2019 at $1,499 and has fallen 91.4% since, to $129 in 2025.
Across 38 payments — averaging $80.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Beaver-visitec International, Inc.$650
- Regeneron Healthcare Solutions, Inc.$292
- Apellis Pharmaceuticals, Inc.$103
- Biogen$100
- Alimera Sciences, Inc.$99
- plus $461 from 9 others
What the payments were for
- Consulting fees$65021%
- Travel & lodging$66622%
- Food & beverage$1,72957%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 5 | $1,339 |
| Beaver-visitec International, Inc. | 1 | $650 |
| Regeneron Healthcare Solutions, Inc. | 7 | $292 |
| Apellis Pharmaceuticals, Inc. | 5 | $103 |
| Biogen | 1 | $100 |
| Alimera Sciences, Inc. | 6 | $99 |
| Bausch & Lomb Americas Inc. | 1 | $96 |
| AstraZeneca | 1 | $91 |
| Dompe US, Inc. | 1 | $76 |
| Genentech USA, Inc. | 3 | $52 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| AbbVie | 2 | $34 |
| Harrow Eye, LLC | 1 | $18 |
| Genentech, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,045 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 56 | $3,650 |
| Ketorolac Tromethamine | 53 | $1,794 |
| Atropine Sulfate | 33 | $996 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 73 | $711 |
| Latanoprost | 44 | $460 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $449 |
| ErythromycinErythromycin Base | 21 | $249 |
| Timolol Maleate | 18 | $146 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Little Silver
- Martin UramLittle Silver$53K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.